[1] Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. DOI:
10.1016/j.envres.2020.109858[2] Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. DOI:
10.1128/JVI.01196-12[3] Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. DOI:
10.1007/s10227-001-0134-6[4] Michael P Schn, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. DOI:
10.1038/sj.jid.5700286
